Tom Maniatis is a founder of Kallyope, and head of the Maniatis lab at Columbia University. Among other things, he's founded several biotechs and authored a manual nicknamed 'the bible of cloning.' His conversation with Nature Biotechnology covers being the first in his family to go to college, the moratorium on recombinant DNA research in Cambridge, Massachusetts, and his long relationship with Jim Watson at Cold Spring Harbor.

Hosted on Acast. See acast.com/privacy for more information.

Tom Maniatis is a founder of Kallyope, and head of the Maniatis lab at Columbia University. Among other things, he's founded several biotechs and authored a manual nicknamed 'the bible of cloning.' His conversation with Nature Biotechnology covers being the first in his family to go to college, the moratorium on recombinant DNA research in Cambridge, Massachusetts, and his long relationship with Jim Watson at Cold Spring Harbor. For information regarding your data privacy, visit acast.com/privacy

Daniel Cohen is chairman and CEO of Pharnext. He was also co-founder of CEPH, Genethon and Millennium, and an early leader in the genomics field. His talk with Nature Biotechnology covers the industrialization of genomic sequencing, his part in founding Millennium and why the conductor has the most difficult job in an orchestra.

Hosted on Acast. See acast.com/privacy for more information.

Daniel Cohen is chairman and CEO of Pharnext. He was also co-founder of CEPH, Genethon and Millennium, and an early leader in the genomics field. His talk with Nature Biotechnology covers the industrialization of genomic sequencing, his part in founding Millennium and why the conductor has the most difficult job in an orchestra. For information regarding your data privacy, visit acast.com/privacy

Daniel Cohen discusses the industrialization of genomic sequencing, his part in founding Millennium and why the conductor has the most difficult job in an orchestra.

James Wilson is the director of the Gene Therapy Program at the University of Pennsylvania. He is also a founder and chief scientific advisor at Regenx Bio, as well as founder and chairman of scientific advisory council at Dimension Therapeutics. Wilson's conversation covers his love of motocross racing, the triumphs and tribulation of gene therapy (including the Jesse Gelsinger tragedy), and the future of drug pricing.

Hosted on Acast. See acast.com/privacy for more information.

James Wilson is the director of the Gene Therapy Program at the University of Pennsylvania. He is also a founder and chief scientific advisor at Regenx Bio, as well as founder and chairman of scientific advisory council at Dimension Therapeutics. Wilson's conversation covers his love of motocross racing, the triumphs and tribulation of gene therapy (including the Jesse Gelsinger tragedy), and the future of drug pricing. For information regarding your data privacy, visit acast.com/privacy

Nature Biotechnology talked to Wilson about his love of motocross racing, the triumphs and tribulation of gene therapy (including the Jesse Gelsinger tragedy), and the future of drug pricing.

Bill Rutter is founder, chairman and CEO of Synergenics, which manages a consortium of biotech companies. He was also a founder of Chiron and is credited with bringing the University of California at San Francisco to its prominent position in life sciences research. His discussion with Nature Biotechnology covers building out the labs at UCSF, sequencing the hepatitis C virus and his short stint in the Navy.

Hosted on Acast. See acast.com/privacy for more information.

Bill Rutter is founder, chairman and CEO of Synergenics, which manages a consortium of biotech companies. He was also a founder of Chiron and is credited with bringing the University of California at San Francisco to its prominent position in life sciences research. His discussion with Nature Biotechnology covers building out the labs at UCSF, sequencing the hepatitis C virus and his short stint in the Navy. For information regarding your data privacy, visit acast.com/privacy